bluuebunny/crossref_metadata_2025_split huggingface dataset:
2468. Is On-Demand Multilocus Sequence Typing of Methicillin-resistant Staphylococcus aureus (MRSA) and Clostridioides difficile Hospital Isolates Useful for Infection Control Practice?
Authors: Holodniy Mark , Winters Mark , Aseo Rowena , Markman Laura , Chary Aarthi 
Published: October 2019

Abstract

Background
MRSA and C. diff are important causes of hospital-onset (HO) or healthcare-associated infections (HAI). Molecular sequencing of bacterial pathogens is often used retrospectively during outbreak investigations to determine phylogenetic linkage. We evaluated the utility of on-demand multilocus sequence typing (MLST) in characterizing hospital transmission events.

Methods
Using VA or NHSN criteria, inpatients with MRSA-HAI or HO-C. difficile infection (HO-CDI) were identified by infection preventionists (IPs) for MLST (by time and location) during active hospital surveillance starting October 2016 or September 2017 (for C. difficile and MRSA, respectively) through March 2019. Vitek 2 identified MRSA from blood or other sources, and stool samples positive for C. difficile by Cepheid Xpert® C. difficile or FilmArray® Gastrointestinal (GI) Panel were collected and C. diff isolated on CCFA plates. Sequence types (STs) were generated by Sanger sequencing and MLST using standard protocols (pubmlst.org). C. difficile genes included adk, atpA, dxr, glyA, recA, sodA, tpi. MRSA genes included arc, aro, glp, gmk, pta, tpi, yqil. Staphylococcal protein A gene (spa) type was determined by spa gene sequencing.

Results
MLST assay (C. diff 33, MRSA 26) intervals ranged from 1–4 weeks based on IP request. 109 C. diff isolates from 105 patients representing 44 STs (10 unique) were found. ST1 and ST2 (27, 20) were most common. 5 patients had 2–3 identical ST isolates over 21–180 days. Of 72 HO-CDI identified, 9 possible person-to-person transmissions events (33 cases) were ruled out; 3 events (9 cases) were ruled in; 14 events (21 cases) were not resolved due to missing samples or no growth. 100 MRSA isolates from 96 patients representing 26 STs (9 unique) were found. ST8/spa t008 (USA300) and ST5/spa t002 (USA100) (44, 29) were most common. 11 patients had 2–3 identical ST isolates over 2–367 days. Of 16 MRSA-HAI identified, 1 transmission event (4 cases) was ruled out, 1 event (2 cases) lacked one strain and was unresolvable.

Conclusion
Common MRSA and C. diff STs predominated among hospital isolates, yet significant heterogeneity was seen over a 2-year period and few true transmission events were documented. On-demand MLST-augmented IP surveillance was useful to rule-out hospital transmission.

Disclosures
All authors: No reported disclosures.
2472. Point Prevalence of Healthcare-Associated Infections and Antibiotic Use in a Tertiary Care Teaching Hospital in Nepal: A Cross-Sectional Study
Authors: Kumar. Shrestha Sailesh , Shrestha Swarup 
Published: October 2019

Abstract

Background
Healthcare-associated infections (HAIs) are a growing threat to patient safety, particularly in resource-limited settings. Information on the burden of HAIs will help in surveillance and prevention efforts. This study aims to estimate the prevalence of HAIs and antibiotics use in a tertiary care teaching hospital in Nepal.

Methods
We conducted a descriptive cross-sectional point prevalence survey in a 350 bedded acute care teaching hospital at Kathmandu, Nepal on April 2019 in a single day for every ward. We studied all the patients aged ≥ 18 years admitted for at least two calendar days on the day of the survey to collect data on patient characteristics, hospital stay, and invasive devices and antibiotics used. We evaluated for the three common HAIs – pneumonia, urinary tract infection and surgical site infection, active on the day of data collection using the clinical criteria by European Center for Disease Prevention and Control protocol version 5.3. We summarized continuous variables with median and interquartile range (IQR) and categorical variables with proportions. We reported the prevalence of HAIs as a proportion of the number of HAIs by the number of patients studied.

Results
Of 213 inpatients, 160 were eligible, 25 (15.6%) among them were from critical care units. The median age was 50 years (IQR 34–65). The median duration of hospital stay was 6 days (IQR 4–9). There were 18 HAIs for the prevalence of 11.25%. Urinary tract infection was the most common HAI (13 HAIs, 72.2% of all HAIs). We found invasive devices used in 42 patients (26.2%), the most common was urinary catheter (37 patients, 23.1%). The number of patients with any antibiotic used was 114 (71.25%) with 61 (38%) patients receiving two or more antibiotics. Third-generation Cephalosporins were the most common antibiotics (74, 64.9%) used. We found 91 (79.8%) patients being treated for community-acquired infections.

Conclusion
This study provides an estimate of the burden of HAIs in our center that is comparable to that of the reports from other resource-limited settings. However, we believe a higher burden will be revealed when we add microbiological criteria as well to diagnose HAIs. This highlights an urgent need for HAI surveillance system, infection prevention and control, and antibiotics stewardship programs in our center.

Disclosures
All authors: No reported disclosures.
2474. The 10 Years Scientific Contribution of the Cologne Cohort of Neutropenic Patients (CoCoNut) for Evaluating Treatment and Outcome of Healthcare-associated Infections
Authors: Jakob Carolin , Heimann Sebastian , Classen Annika , Gillis Meyke , Thelen Philipp , Holtick Udo , Scheid Christof , Cornely Oliver , Janne Vehreschild Jörg 
Published: October 2019

Abstract

Background
Healthcare-associated infections (HAIs) are a leading cause for morbidity and mortality in neutropenic patients.

Methods
The Cologne Cohort of Neutropenic Patients (CoCoNut) is an ongoing, prospective, longitudinal cohort, collecting inpatient data for analysis of epidemiology, risk factors, and outcome of neutropenic patients (at least one day of absolute neutrophil count < 500/µL) at risk for HAIs. The CoCoNut contains comprehensive data, i.e. patient characteristics, medication, chemotherapy, clinical data (e.g., diarrhea, body temperature), as well as laboratory, microbiological, virologic, and radiological results. The purpose of this cohort is to improve the knowledge on HAIs and management of anti-infective prophylaxis and therapy.

Results
To date, the CoCoNut includes 8,176 inpatient stays from 3,354 neutropenic patients treated at the hematology/oncology department of the University Hospital of Cologne between January 2009 and December 2018. Hodgkin and Non-Hodgkin lymphoma (32%), acute leukemia (28%), and chronic leukemia (10%) were the predominant underlying diseases; comprising 843/8,176 (10%) inpatient stays with allogenic stem cell transplantation. The overall number of neutropenic days and fever days (body temperature ≥ 38 °C) was 56,824 and 25,347, respectively. Blood stream infections (occurrence of fever and positive blood culture) occurred in 1,283/8,176 (16%) inpatient stays, and the overall mortality rate was 9% (n = 716/8,176). By now, 17 peer-reviewed articles analyzing epidemiology, treatment, and outcome of HAIs were published based on data from the CoCoNut.

Conclusion
Data extracted from the CoCoNut underlines the important role of evaluating innovative treatment strategies. Considering the remaining high infection rate for HAIs of neutropenic patients, the growing development of antimicrobial drug resistance, and the existing powerful methods for data processing (e.g., artificial intelligence), we will continue to utilizing and expanding the CoCoNut in the future.

Disclosures
All authors: No reported disclosures.
2475. Incidence of Multidrug-Resistant, Extensively Drug-Resistant and Pandrug-Resistant Gram-Negative Bacteria in Brazilian Intensive Care Units
Authors: Souza Gregory Lauar , Rocha Rhayssa Fernanda de Andrade , Silveira Andressa Do nascimento , Dias Duarte de Carvalho Handerson , Oliveira Cristóvão D M , Leite Edna M M , Silva Estevão Urbano , Giarola Lucca G , Couto Bráulio R G M , Starling Carlos E F 
Published: October 2019

Abstract

Background
The Centers for Disease Control and Prevention (CDC) proposed standard definitions for acquired resistance in bacterias. Resistant bacteria were categorized as multidrug-resistant (MDR), extensively drug-resistant (XDR) and pandrug-resistant (PDR). This study describes the incidence of Gram-negative MDR, XDR and PDR in 12 private and adult intensive care units (ICU’s) from Belo Horizonte, Minas Gerais, the sixth most populated city in Brazil, with approximately 3 million inhabitants.

Methods
Data were collected between January/2013 to December/2017 from 12 ICU’s. The hospitals used prospective healthcare-associated infections (HAI) surveillance protocols, in accordance to the CDC. Antimicrobial resistance from six Gram-negatives, causing nosocomial infections, were evaluated: Acinetobacter sp., Klebsiella sp., Proteus sp., Enterobacter sp., Escherichia coli, and Pseudomonas sp.. We computed the three categories of drug-resistance (MDR+XDR+PDR) to define benchmarks for the resistance rate of each Gram-negative evaluated. Benchmarks were defined as the superior limits of 95% confidence interval for the resistance rate.

Results
After a 5 year surveillance, 6,242 HAI strains were tested: no pandrug-resistant bacteria (PDR) was found. Acinetobacter sp. was the most resistant Gram-negative: 206 strains from 1,858 were XDR (11%), and 1,638 were MDR (88%). Pseudomonas sp.: 41/1,159 = 3.53% XDR; 180/1,159 = 15.53% MDR. Klebsiella sp.: 2/1,566 = 0,1% XDR; 813/1,566 = 52% MDR. Proteus sp.: 0/507 = 0% XDR; 163/507 = 32% MDR. Enterobacter sp.: 0/471 = 0% XDR; 148/471 = 31% MDR. Escherichia coli: 0/681 = 0% XDR; 157/681 = 23% MDR. Benchmarks for the global resistance rate of each Gram-negative (MDR+XDR+PDR): Acinetobacter sp. = 92%; Klebsiella sp. = 62%; Proteus sp. = 40%; Enterobacter sp. = 48%; Escherichia coli = 33%; Pseudomonas sp. = 30%.

Conclusion
This study has calculated the incidence of Gram-negative MDR, XDR and PDR, and found a higher incidence of MDR Acinetobacter sp., with an 88% multiresistance rate. Henceforth, developing countries healthcare institutions must be aware of an increased risk of infection by Acinetobacter sp.. Benchmarks have been defined, and can be used as indicators for healthcare assessment.

Disclosures
All authors: No reported disclosures.
2476. External and Internal Validation of the Healthcare-associated Infection Data in the Korean National Healthcare-associated Infectious Surveillance System (KONIS)
Authors: Kwak Yee Gyung , Song Je Eun , Choi Young Hwa , Kim Sung Ran , Han Su Ha , Yoo So-Yeon , Yoo Hyeon Mi , Choi Ji-youn , Shin Myoung Jin , Choi Jun yong , Lee Sang-Oh , Kim Hong Bin , Lee Mi Suk , Kim Tae Hyong , Park Sun Hee , Choe Pyoeng Gyun , Kim Young Keun 
Published: October 2019

Abstract

Background
National surveillance data should be validated to identify data quality issues. This study tested the validity of healthcare-associated infection (HAI) data in the Korean National Healthcare-associated Infections Surveillance System (KONIS), intensive care unit (ICU) module.

Methods
The validation process consisted of external (EV) and internal (IV) validation phases. For the 10 hospitals that were selected based on the HAI rate, among the 193 participating hospitals between July 2016 and June 2017, both EV and IV were performed. For the EV, the validation team reviewed 295 medical records of 60 patients with reported HAIs, including 20 urinary tract infections (UTIs), 27 bloodstream infections (BSIs), and 13 cases of pneumonia (PNEU), and 235 patients with no reported HAI during 1-day visits conducted in November and December 2017. The reviewer’s diagnosis of HAI was regarded as the reference standard. IV was conducted by the staff of each hospital and evaluated whether UTI or BSI were present. Primary IV was performed for 279 patients who were subject to EV. Secondary IV was performed on 203 patients in another 11 selected participating hospitals that did not report HAIs to KONIS during the 1-year study period.

Results
In the EV, the diagnosis of UTI in the participating hospitals had a sensitivity of 72.0% and specificity of 99.3%. The sensitivity of BSI and PNEU was 63.2% and 70.6%, respectively, and specificity was 98.8% and 99.6%. The agreement (kappa) between the EV and primary IV was significant, with κ = 0.754 for UTI and κ = 0.674 for BSI. The results of the secondary IV showed that the hospitals that had no reports of HAI had few hospital beds and performed few blood or urine culture tests. In the secondary IV, eight UTIs and three BSIs were newly diagnosed in three hospitals, respectively. The reasons for not reporting the HAIs were presumed to be a lack of understanding of the surveillance standards and fear of the disadvantages of disclosing the HAI.

Conclusion
This study shows the need for ongoing validation and continuous training of surveillance personnel to maintain the accuracy of surveillance data. We also confirmed that IV can be used as an alternative monitoring method to examine validity and accuracy.

Disclosures
All authors: No reported disclosures.
2477. Antimicrobial Resistance patterns of Enterobacteriaceae and Pseudomonas aeruginosa from Colombian clinical isolates. 2017–2018
Authors: Rojas Monica Maria Rojas , López Catalina , Ruiz Jaime , Pavía Jacquleine , Oñate Jose , Hernández-Gómez Cristhian 
Published: October 2019

Abstract

Background
The Study for Monitoring Antimicrobial Resistance Trends (SMART) is a worldwide initiative to monitor in vitro susceptibility of clinical Gram-negative isolates to several antimicrobial agents. Surveillance initiatives are essential to provide real-world evidence to support local guidelines development. Colombia has participated since 2012 with isolates from complicated intrabdominal infections (cIAI), complicated urinary tract infections (cUTI) and respiratory tract infections (RTI). This study describes resistant patterns of Escherichia coli (Eco), Klebsiella pneumoniae (Kpn) and Pseudomonas aeruginosa (Pae) clinical isolates collected in Colombian hospitals in a 2 years period (2017–2018).

Methods
Isolates from patients with cIAI, cUTI and RTI were collected. Identification confirmation was done in central laboratory. Minimum inhibitory concentrations (MIC) were performed by broth microdilution and interpreted according to 2018 CLSI guidelines, same criteria for Extended-spectrum β-lactamase (ESBL) classification. The antimicrobial activity was evaluated for aztreonam (ATM), ceftolozane/tazobactam (C/T), ceftazidime (CAZ), colistin (COL), ertapenem (ETP), cefepime (FEP), imipenem (IMP), meropenem (MEM) and piperacillin–tazobactam (TZP).

Results
During 2017–2018, 1492 isolates were collected. The main organism was Eco (51%) followed by Kpn (29%) and Pae (20%). In vitro susceptibility activity is presented in Table 1. COL, C/T, ETP, MEM and IPM exhibited over 95% susceptibility in Eco. ESBL prevalence was 18% for Eco (53/314) and 22% for Kpn (36/165). COL and C/T were the most active agents against Pae isolates. For Kpn, MIC50/90 values were: MEM (0.12 / 8), C/T (0.5 / 8) and for TZP (8 / > 64), meanwhile for Pae were MEM (0.5 / 32), C/T (0.5 / 32) and for TZP (8 / > 64).

Conclusion
Continued antimicrobial resistance surveillance initiatives are critical to guide the empiric treatments decision in a multidrug resistance era. This study shows that Ceftolozane/Tazobactam, MEM and COL have the best susceptibility profile against Eco, Kpn and Pae of cIAI, cUTI and RTI cases in Colombia. The C/T susceptibility rates and low MIC distribution provide evidence to support its use as a non-carbapenem therapeutic alternative for Gram-negative infections.

Disclosures
All authors: No reported disclosures.
2481. Comparing inter-hospital patient movement patterns to better understand mechanisms for regional dissemination of carbapenem-resistant Enterobacteriaceae
Authors: Wolford Hannah , O’Hagan Justin , Paul Prabasaj , Reddy Sujan , Attell Brandon , Jernigan John A , Slayton Rachel 
Published: October 2019

Abstract

Background
Understanding inter-hospital movement of patients provides insight into regional transmission of multidrug-resistant organisms (MDROs) that can guide containment efforts. Movement of general patient populations are often used for this purpose, but movement of the specific patient population of MDRO carriers may be more useful. We sought to compare movement of CRE patients with that of other patient populations to explore whether CRE carriers move differently, and if so, to determine whether administrative data can be used to identify patient populations with transfer patterns that mimic CRE patients.

Methods
We used New York’s Statewide Planning and Research Cooperative System (SPARCS), to create a patient network of all acute care hospital encounters (“overall hospital population”) during 2013–2015. We identified the subset of CRE cases in the network by linking the SPARCS data to CRE cases reported to the National Healthcare Safety Network in 2014, matching on admission date, date of birth, gender, and facility. We described patient characteristics and movement patterns across 3 cohorts: (1) CRE cases, (2) overall hospital population, (3) CRE surrogate (patients clinically similar to CRE cases based on length of stay [LOS] ≥14 days and Clinical Classification Software [CCS] category of sepsis plus at least one of the following additional CCS categories: adult respiratory failure, acute renal failure, procedure complication or device complication). Correlations between cohorts were calculated using patient transfer matrices to determine similarities between the networks.

Results
The average LOS for CRE cases was 25× higher than the overall hospital population (31.4 vs. 1.3 days, Figure 1a), and CRE cases were more likely to die or be discharged to a skilled nursing facility (Figure 1b). CRE movement networks were only moderately correlated with the overall hospital population (R2 = 0.51); there was higher correlation between CRE case and CRE surrogate networks (R2 = 0.73).

Conclusion
CRE patients have different healthcare experiences in the hospital and between hospitals in New York compared with the overall hospital population. The CRE surrogate cohort transfer patterns were more similar, and could be used to understand CRE patient movement in the absence of CRE culture data.

Disclosures
All authors: No reported disclosures.
2486. Clinical Outcomes of Patients Treated with Dolutegravir Functional Monotherapy or Dolutegravir plus an Active Non-cytosine Nucleoside Analog: A Retrospective Observational Cohort Study of Treatment-Experienced Patients
Authors: Rolle Charlotte-Paige M , Bryant Beth , Tucker Colton J , Camila Castro Maria , Nguyen Vu , Hinestrosa Federico , DeJesus Edwin 
Published: October 2019

Abstract

Background
Dual dolutegravir (DTG)-containing regimens (DCRs) are currently approved for the treatment of antiretroviral (ARV) naïve and experienced patients with HIV-1 infection. DTG monotherapy has resulted in unacceptable rates of virologic failure and subsequent development of DTG resistance. Here, we evaluate the “real-world” efficacy and “barrier to resistance” of DCRs containing 0–1 active ARVs.

Methods
This is a retrospective observational study evaluating clinical outcomes of treatment-experienced patients on combination DCRs found to be on DTG functional monotherapy or DTG plus an active non-cytosine analog between 2013 and 2014. The primary endpoint was virologic suppression (HIV-1 RNA< 50 copies/mL) at week 48. Virologic failure (VF) was defined as confirmed HIV-1 RNA≥ 50 copies/mL 12 weeks after initiating DTG or any time after achieving HIV-1 RNA< 50 copies/mL. Adherence, adverse events (AEs) and laboratory parameters were analyzed throughout the study.

Results
Thirty-nine patients were included in the analysis, 19 (49%) were on DTG functional monotherapy and 20 (51%) were on DTG plus a non-cytosine nucleoside analog. The median age (range) was 53 (40–74) years, median baseline CD4+ count (range) was 564 (92–1217) cells/mm3, 22 (56%) had baseline HIV-1 RNA< 50 copies/mL, and 24 (62%) had previously used INSTIs (Table 1). At Weeks 48 and 96, virologic suppression was observed in 78.3% and 86% of patients respectively (Figures 1 and 2). Among 7 VFs (2 on DTG functional monotherapy, 5 on DTG plus a non-cytosine nucleoside analog), there was no evidence of treatment-emergent resistance to DTG. There was a significant median increase in CD4+ count from baseline to Week 48 (+90 cells/mm3, 95% confidence interval: [14.18, 165.9]). No significant changes in lipid parameters were observed. Treatment-related AEs occurred in 17/39 (44%) patients (all Grade 1–2) and 1 patient discontinued DCR treatment due to rash.

Conclusion
In this “real-world” cohort of treatment-experienced patients, we observed that DTG functional monotherapy and DTG plus a non-cytosine nucleoside analog maintained long-term virologic control and was well tolerated. These data supports use of DTG as a partner for dual DCRs given its high efficacy in patients with underlying ARV resistance.

Disclosures
All authors: No reported disclosures.
2499. Perceptions of and Preferences for Oral or Long-Acting Injectable Antiretroviral Treatment Regimens in the United States and Canada
Authors: Garris Cindy , Heidenreich Sebastian , Arthurs Erin , Spinelli Frank , Cutts Katelyn , Lowman Erik , Rice Howard L , Lebouche Bertrand , Collacott Hannah , Nie Chua Gin , Gelhorn Heather 
Published: October 2019

Abstract

Background
Antiretroviral treatment (ART) for patients living with HIV (PLHIV) has improved greatly, however, challenges with daily oral dosing remain. New ART options with reduced dosing frequency and innovative delivery methods may help address these challenges. This study assesses patient and physician satisfaction with current treatments and preferences for switching to a monthly or every other month long-acting injectable (LAI) ART.

Methods
This is a cross-sectional online survey of PLHIV and physicians treating PLHIV in United States and Canada. A literature review, clinical expert input, and qualitative and quantitative pilots informed survey design. Eligible PLHIV were on ART for ≥ 6 months and virally suppressed (self-reported). Survey questions for patients evaluate satisfaction and adherence to current ART. Treatment preferences are assessed using a discrete choice experiment (DCE), where respondents choose between staying on current ART, switching to another oral ART or switching to a LAI ART. DCE treatment attributes include dosing frequency, side effects, forgivability, food/mealtime restrictions, and mode of administration. Pilot data for US patients is included here; the main survey will include approximately 550 patients and 450 physicians.

Results
Of 51 PLHIV completing the pilot survey, 80% were male, mean age was 54 years, and 63% were on ART for ≥10 years. Switching ART was common, with 55% reporting changing their ART ≥ 3 times. Just under half of patients (47%) were not totally satisfied with their current ART. Most common reasons for dissatisfaction included daily reminder of having HIV (31%) and having to take medicine every day (28%). Just over a quarter of patients (28%) reported forgetting to take their ART in the prior month. Across all DCE choices, patients preferred to remain on their current treatment 47% of the time, while 45% of the time patients preferred switching to the LAI, and for the remaining 8%, patients chose switching to another oral ART regimen.

Conclusion
Despite advances in ART, treatment challenges remain. Among the treatment-experienced PLHIV in this pilot survey, over half of their choices resulted in switching to an alternative regimen, and when opting to switch, most patients preferred the long-acting injectable treatment regimen.

Disclosures
All authors: No reported disclosures.